HOME >> BIOLOGY >> NEWS
Candidate hookworm vaccine shows benefits in animal study

A paper published in this week's PLoS Medicine shows that vaccination against a protein secreted by the dog hookworm can protect against blood loss and anaemia caused by the same hookworm in dogs. The researchers, led by Alex Loukas and Peter Hotez, showed that vaccination of dogs with recombinant Ac-APR-1, an enzyme that starts the digestion of hemoglobin in hookworms, induced an immune response and resulted in significantly reduced hookworm burdens and fecal egg counts in vaccinated dogs compared to control dogs after challenge with infective larvae of the hookworm Ancylostoma caninum. Most importantly, vaccinated dogs were protected against blood loss and most did not develop anemia, the major result of hookworm disease.

Hookworms are intestinal parasites of mammals, including humans, dogs, and cats; in humans these infections are a leading cause of intestinal blood loss and iron-deficiency anemia. Hookworm infections occur mostly in tropical and subtropical climates and are estimated to infect about 1 billion people worldwide-- about one-fifth of the world's population. People who have direct contact with soil that contains human feces in areas where hookworm is common are at high risk of infection; because children play in dirt, they are at the highest risk.

These results set the stage for the next stage of vaccine development in humans. Loukas and colleagues suggest that the ideal hookworm vaccine would be a mixture of two recombinant proteins, targeting both the infective larva and the blood-feeding adult stage (as targeted here) of the parasite. Such a vaccine would limit the amount of blood loss caused by feeding worms and maintain normal levels of hemoglobin.


'"/>

Contact: Paul Ocampo
press@plos.org
415-624-1224
Public Library of Science
3-Oct-2005


Page: 1

Related biology news :

1. Candidate research sites selected for the National Ecological Observatory Network
2. Designed peptides: Candidates for the treatment of cancer, sexual dysfunction, eating disorders
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
5. Handicapping tuberculosis may be the way to a better vaccine
6. Developing a more effective vaccine for tuberculosis
7. New target for HIV/AIDS drugs and vaccine discovered
8. Genomic analysis uncovers new targets for HIV vaccine
9. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
10. Universal flu vaccine being tested on humans
11. From clinical cancer research: rethinking therapeutic cancer vaccine trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
Breaking Biology Technology:
Cached News: